Neonatal Immunization With Pneumococcal Conjugate Vaccine In Papua New Guinea
Funder
National Health and Medical Research Council
Funding Amount
$1,181,966.00
Summary
One million children die every year of pneumococcal (Pnc) disease, the majority in the third world. Many die in early infancy and babies may benefit from immunisation with a Pnc conjugate vaccine (PrevenarTM) at birth. The Papua New Guinea (PNG) Insatiate of Medical Research; Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia, will collaborate to closely examine the safety of this approach, particularly with regard to impact on the dev ....One million children die every year of pneumococcal (Pnc) disease, the majority in the third world. Many die in early infancy and babies may benefit from immunisation with a Pnc conjugate vaccine (PrevenarTM) at birth. The Papua New Guinea (PNG) Insatiate of Medical Research; Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia, will collaborate to closely examine the safety of this approach, particularly with regard to impact on the development of immunity and response to other vaccines given to infants. This study will also provide a unique opportunity for training of PNG and Australian scientists in both countries; transfer state-of-the-art immunological technology and stimulate further collaborations on respiratory infections in the region.Read moreRead less
Determination Of Disease Specific Epitopes In Rheumatic Heart Disease In Australia
Funder
National Health and Medical Research Council
Funding Amount
$374,817.00
Summary
Rheumatic Fever and Rheumatic Heart Disease (RF-RHD) remain a significant cause of illness in Aboriginal communities in Australia. RF-RHD is a complication which follows infection with a specific bacterium. The purpose of this study is to compare the body's response and find out the patterns of antibody and immune cell reactivity to the bacterium and body proteins in RF-RHD patients and controls. It will also enable us to study the mechanisms that initiate the disease process.
Immunomodulatory Molecules Of Parasitic Helminths As Novel Therapeutics For Allergic Disorders.
Funder
National Health and Medical Research Council
Funding Amount
$321,532.00
Summary
Australia has one of the highest rates of asthma in the world with almost 3 million Australians are affected by this disease. Previous research has shown that infection with various types of parasitic worms lessens the severity of asthma. The aim of this research is to find out why this happens and to isolate the ingredients from the parasite that suppress asthma. Once found, these molecules can be used to create new drugs for the prevention of asthma and allergies in children and adults.
Targeting The Human Immune Response To Bacterial Superantigens.
Funder
National Health and Medical Research Council
Funding Amount
$165,424.00
Summary
This research investigates the human immune response to infection with toxin producing bacteria. Toxins activate the human immune system which can lead to serious illness or the development of disease that can progress rapidly and be associated with high rates of morbidity and mortality. Investigating the harmful effects of infection with toxin producing bacteria in humans and the damage caused by their toxins is essential for the development of effective therapeutic strategies.
Differences In Neonatal Immune Regulation In The Developing And Developed World: Implications For Neonatal Vaccinations?
Funder
National Health and Medical Research Council
Funding Amount
$332,083.00
Summary
This project will study the effect of adverse living conditions such as high microbial exposure, malnutrition, environmental tobacco smoke and malaria infection on the development of a newborn's immune system,by comparing immune response between newborns in Papua New Guinea and in Western Australia. This study will help us to understand the high susceptibility of children in the developing world for infectious diseases and to develop better prevention strategies.
Immune Dysregulation In HIV Patients With Immune Reconstitution After Highly Active Anti-retroviral Therapy
Funder
National Health and Medical Research Council
Funding Amount
$411,000.00
Summary
As HIV infection progresses to AIDS, there is a depletion of CD4 T-cells from the patient's blood and inhibition of the function of the remaining cells. Some immune defects resolve if the patient is given treatment with highly active anti-retroviral therapy (HAART), but it remains to be determined if the function of the imune system returns fully to normal. We have shown that problems with the regulation of the restored immune system in the first 6 months of treatment can lead to diseases associ ....As HIV infection progresses to AIDS, there is a depletion of CD4 T-cells from the patient's blood and inhibition of the function of the remaining cells. Some immune defects resolve if the patient is given treatment with highly active anti-retroviral therapy (HAART), but it remains to be determined if the function of the imune system returns fully to normal. We have shown that problems with the regulation of the restored immune system in the first 6 months of treatment can lead to diseases associated with Mycobacterial infections (eg: tuberculosis), CMV retinitis, hepatitis B virus or hepatitis C virus. We have defined these conditions as Immune Restoration diseases (IRD) and shown that they occur in one in four individuals who begin HAART from low baseline CD4 T-cell counts. IRD are likely to become common as therapy becomes available in Africa and Asia as patients begin treatment from low CD4 T-cell counts. There is also emerging evidence that dysregulated T-cell responses may cause disease later in the course of immune reconstitution. For example, some patients with undetectable HIV experience opportunistic infections or autoimmune disease after many months of HAART. This project will use West Australian patients receiving optimal therapy for their HIV infection. We will analyse immune activation and T-cell function in patients beginning HAART with low CD4 T-cell counts and patients who have had well-controlled HIV infection for at least 6 months. Blood samples will be collected for the measurement of immunological messengers (cytokines) known to be involved in different types of immune responses. The results will be correlated with the clinical outcome.Read moreRead less
This project will determine how viruses prevent transmission of messages within cells which orchestrate responses of our immune system to infection and whether our current therapies improve this defect. This knowledge will help us to better understand why our immune system is not able to control chronic virus infection and improve therapies for these diseases.
Improving Protection Against Childhood Tuberculosis: The Influence Of BCG Vaccine Strain And Age On Protective Immunity
Funder
National Health and Medical Research Council
Funding Amount
$473,739.00
Summary
BCG vaccine is of vital importance in the fight against the increasing problem of TB worldwide, particularly in children. This project will compare the 3 most commonly used different strains of BCG vaccine to determine which produces the best protective immunity in newborns. It will also determine whether BCG at birth or at 2 months of age provides better protection. Optimising the timing and strain used for BCG immunisation would prevent large numbers of cases and deaths from TB at low cost.
Protecting Hyposplenic Children And Adults: Identifying Optimal Immunisation Regimens
Funder
National Health and Medical Research Council
Funding Amount
$472,044.00
Summary
Children and adults without normal spleen function are at massively increased risk of overwhelming infection with the pneumococcus bacteria, with 200 times the risk of death from sepsis compared with the normal community. Poor spleen function can be due to an absent spleen (eg after surgery following a car accident) or an underlying medical condition (eg thalassaemia or cancer therapy). Thousands of Australians are affected by this condition and need extra protection from daily antibiotics and a ....Children and adults without normal spleen function are at massively increased risk of overwhelming infection with the pneumococcus bacteria, with 200 times the risk of death from sepsis compared with the normal community. Poor spleen function can be due to an absent spleen (eg after surgery following a car accident) or an underlying medical condition (eg thalassaemia or cancer therapy). Thousands of Australians are affected by this condition and need extra protection from daily antibiotics and additional immunsiations against pneumococcus. A new vaccine against pneumococcus was introduced for Australian infants routinely in 2005 and has prevented many from developing pneumococcal meningitis, sepsis and pneumonia. We wish to see whether this new vaccine, when used with the older existing pneumococcal vaccine, will better protect older children and adults with poor spleen function from the devastating effects of pneumococcus. We will compare different ways of using these vaccines to try to identify the most protective vaccination plan for this vulnerable group of Australians.Read moreRead less